Pentixapharm Holding AG Appoints Erik Merten to Executive Board

Pentixapharm Holding AG has announced the appointment of Erik Merten to its Executive Board. This strategic move comes as the company gears up for its Phase 3 PANDA program, aiming to enhance its readiness for commercialization. Merten, previously Head of Chemistry, Manufacturing, and Controls at Pentixapharm, will assume the role of Chief Technology Officer. He will work alongside CEO Dirk Pleimes and CBO Henner Kollenberg.

The company, active in radiopharmaceutical development, is focused on the commercialization of its diagnostic asset, Pentixafor. Merten's extensive experience at Bayer, where he led strategic product development, will be crucial for Pentixapharm's manufacturing and supply strategy. Andreas Eckert, Chairman of the Supervisory Board, emphasized Merten's 25 years in the industry as vital for advancing their Phase 3 program.

This appointment reinforces Pentixapharm's ability to execute its clinical and commercial strategies successfully.